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Key Points
•BET inhibitor therapy
upregulates HDAC6
expression, which limits
the efficacy of this drug
class.
•Cotargeting of HDAC6
and BET proteins leads
to enhanced reduction
of c-MYC expression
and yields synergistic
anti-MM activity.
Inhibition of bromodomain and extra terminal (BET) protein family members, including
BRD4, decreases the expression of c-MYC and other key oncogenic factors and also
signiﬁcantly induces histone deacetylase 6 (HDAC6) expression. On the basis of the role
of HDAC6 in malignant pathogenesis, we hypothesized that rational cotargeting of
HDAC6 and BET family proteins may represent a novel approach that yields synergistic
antimyelomaactivity.Weused genetic andpharmacologic approaches to selectively impair
HDAC6 and BET function and evaluated the consequential impact on myeloma pathogen-
esis. These studies identiﬁed HDAC6 upregulation as an eﬃcacy reducing mechanism for
BET inhibitors because antagonizing HDAC6 activity synergistically enhanced the activity
of JQ1 in a panel of multiple myeloma (MM) cell lines and primary CD1381 cells obtained
from patients with MM. The synergy of this therapeutic combination was linked to
signiﬁcant reductions in c-MYC expression and increases in apoptosis induction.
Administration of the clinical HDAC6 inhibitor ricolinostat was very well tolerated
and signiﬁcantly augmented the in vivo antimyeloma activity of JQ1. Ex vivo
pharmacodynamic analyses demonstrated that the combination of JQ1 and ricolinostat
led to signiﬁcantly lower MM cell proliferation and increased apoptosis and diminished
expression of c-MYC and BCL-2. These data demonstrate that cotargeting of HDAC6
and BET family members is a novel and clinically actionable approach to augment the
eﬃcacy of both classes of agents that warrants further investigation.
Introduction
MYC oncoproteins are overexpressed in nearly 70% of human tumors such as multiple myeloma (MM) in
which constitutive MYC activation is a frequent pathogenic event that drives oncogenesis.1 Given that
aberrant MYC transcriptional activity increases the levels of several genes that are associated with disease
progression and drug resistance, MYC inhibition is a highly appealing therapeutic strategy. Recent studies
have demonstrated that targeting bromodomain and extra terminal (BET) protein family members
decreases the expression of c-MYC and has significant antimyeloma activity.2,3 In addition, overexpression
of BRD4 or BRD2 has been reported in various cancer types, suggesting that they may be key therapeutic
targets.2,4 Consistent with this, the displacement of BRD4 from chromatin with the BET inhibitor JQ1
inhibits tumor cell proliferation and exhibits significant efficacy against various tumor types.3,5,6
Treatment of cancer cells with BET inhibitors induces a reduction of BRD4 levels at enhancers and
promoters, resulting in significant gene expression changes.3,7 Downregulation of key genes such as
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MYC and BCL-2 may account for the significant anticancer activity
observed after treatment with a BET inhibitor.3,7,8 Considering the
important role of MYC in the pathogenesis of MM, BET inhibitors may
be particularly promising therapeutic agents for this disease.9,10
Consistent with this, BET inhibitors have exhibited significant activity
in preclinical MM studies.2,7,11,12 However, in a recent clinical study,
the BET inhibitor OTX-015 did not display noteworthy activity in
12 patients with MM. This suggests that previously unidentified
resistance mechanisms may be blunting efficacy and that combina-
tion approaches that target key resistance factors could lead to more
potent suppression of MYC activity in this disease.13
Although downregulation of MYC and other oncogenes has been
proposed as a key mechanism of action of BET inhibitors, it is clear
that these agents cause a much broader degree of alteration in
the transcriptome, including the upregulation of factors that may
actually serve to blunt the efficacy of BET inhibition.14-16 With the
goal of developing a new approach to safely improve the potency
of BET inhibitor therapy for MM, we conducted transcriptome
analyses and identified histone deacetylase 6 (HDAC6) as a gene
that was significantly and consistently upregulated after exposure
to JQ1. We previously demonstrated that HDAC6 is a c-MYC
target gene.10 Accordingly, it was recently shown that inactivation
of HDAC6 decreases c-MYC expression.17 Here we report that
treatment with the BET inhibitor JQ1 significantly upregulates
HDAC6 expression in a manner that reduces its anti-MM activity.
To explore whether cotargeting HDAC6 and BET proteins is a
promising strategy for improving therapeutic benefit, we conducted a
series of assays using pharmacologic and genetic approaches to
target both factors. Inhibition of HDAC6 genetically or with the
HDAC6-selective inhibitor ricolinostat decreased c-MYC expression
and strongly potentiated JQ1-mediated MYC suppression and its
antimyeloma activity in MM cell lines and CD1381 cells from MM
patients. In addition, administration of ricolinostat and JQ1 to mice
bearing MM xenografts was well tolerated and significantly antago-
nized disease progression. Analysis of tumor specimens from mice
treated with JQ1 and ricolinostat demonstrated in vivo reduction
of c-MYC and BCL-2 expression along with decreased tumor cell
proliferation and increased apoptosis. Our collective findings establish
the foundation for further investigation of rational cotargeting of BET
proteins and HDAC6 in patients with MM and other malignancies.
Materials and methods
Cells and cell culture
RPMI-8226, U266, NCI-H929, MM.1S, and MM.1R MM cell lines
were obtained from American Type Cell Culture Collection (Manassas,
VA). LP-1, KMS-12-BM, SKMM-2, MOLP-8, EJM, and OPM-2
were purchased from the DSMZ (Braunschweig, Germany). MM
cell lines were maintained in RPMI-1640 media supplemented
with 10% fetal bovine serum in a humidified incubator at 37°C with
5% CO2. Primary human MM cells were obtained from the bone
marrow of MM patients after obtaining informed consent in
accordance with an approved institutional review board protocol
and the Declaration of Helsinki. CD1381 cells were selected using
beads from Miltenyi Biotec (Auburn, CA).
Antibodies and reagents
Antibodies were obtained from the following commercial sources:
anti-c-MYC (Santa Cruz Biotechnology, Santa Cruz, CA); anti-tubulin
(Sigma-Aldrich, St. Louis, MO); anti-p21 (EMD Millipore, Temecula,
CA); anti-a-acetyl tubulin (Lys40), anti-acetyl histone H4 (Lys8), anti-
cleaved anti-caspase-3, anti-BCL-2, and anti-HDAC6 (Cell Signaling,
Danvers, MA); anti-BRD4 (Abcam, Cambridge, MA); anti-proliferating
cell nuclear antigen (PCNA; Dako, Glostrup, Denmark); goat anti-
rabbit horseradish peroxidase (HRP)–conjugated secondary anti-
body (The Jackson Laboratories, West Grove, PA); rat anti-mouse
immunoglobulin G2a (IgG2a)-HRP (Serotec, Raleigh, NC); and
sheep anti-mouse-HRP and donkey anti-rabbit-HRP (Amersham,
Pittsburgh, PA). JQ1, ricolinostat, and vorinostat were purchased
from SelleckChem (Houston, TX).
Immunoblotting
MM cells were harvested and lysed using Triton-X-100 lysis
buffer (1% triton X-100, 150 mM NaCl, 25 mM tris(hydroxymethyl)
aminomethane [Tris] [pH 7.5]). In all, 50 mg of total cellular protein
from each sample was subjected to sodium dodecyl sulfate
polyacrylamide gel electrophoresis, proteins were transferred to
nitrocellulose membranes, and the membranes were blocked with
5% nonfat milk in a Tris-buffered saline solution containing 0.1%
Tween-20 for 1 hour. The blots were probed overnight with relevant
primary antibodies, washed, and probed with species-specific
secondary antibodies coupled to horseradish peroxidase (GE
Healthcare, Pittsburgh, PA). Immunoreactive material was detected
by enhanced chemiluminescence (Protein Simple, Santa Clara, CA).
Quantification of drug-induced cytotoxicity
Cell viability was assessed by 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) assay. MM cells were cultured in
96-well plates at a density of 10 000 cells per well and were treated
with the indicted concentrations of drugs for 72 hours. After drug
treatment, MTT was added, and viability was quantified using a
microplate reader. The proapoptotic effects of JQ1, ricolinostat,
and vorinostat were quantified by propidium iodide staining and
fluorescence activated cell sorting analysis of sub-G0/G1 DNA,
and quantification of active caspase-3–positive cells was performed
by flow cytometry using a commercial kit (BD Biosciences, San Jose,
CA). Combination treatment groups were evaluated, and the
interactions between drugs were determined by calculating Chou-
Talalay combination indices using CompuSyn software (ComboSyn,
Inc., Paramus, NJ). The effects of ricolinostat and JQ1were quantified
by MTT assay.
Expression microarrays
LP-1 and OPM-2 human MM cells were treated with 500 nM JQ1
for 24 hours. After drug treatment, total RNAs were isolated using
the RNeasy Plus Mini Kit (Qiagen, Rockville, MD) and treated with a
TURBO DNA-free Kit (Applied Biosystems, Foster City, CA). In all,
300 ng of total RNA per sample was amplified and hybridized to
GeneChip HumanGene 1.0 ST arrays (Affymetrix, Inc., Santa Clara,
CA) according to the manufacturer’s instructions. Affymetrix CEL
files were imported into Partek Genomics Suite 6.4 (Partek Inc., St.
Louis, MO) using the default Partek normalization parameters and
the robust multiarray average analysis adjusted for probe sequence and
guanine and cytosine robust multiarray average content. Data normal-
ization was performed across all arrays using quantile normalization.
shRNA knockdown of HDAC6 and BRD4
MM cells were infected with a lentivirus encoding a short hairpin
RNA (shRNA) sequence specific for HDAC6, BRD4, or a nontargeted
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control (Santa Cruz Biotechnology) using 5 mg/mL polybrene.
Infected cells were selected with constant culture in 1 mg/mL puromycin.
HDAC6 and BRD4 knockdown were confirmed by immunoblotting.
Lentiviral overexpression of HDAC6
RPMI-8226 MM cells were infected with lenti–open reading frame
particles encoding HDAC6 or a nontargeted control (Origene,
Rockville, MD) using 5 mg/mL polybrene. Infected cells were selected
with constant culture in 1 mg/mL puromycin. HDAC6 overexpression
was confirmed by immunoblotting.
Quantitative RT-PCR
MM cells were treated with 500 nM JQ1, 3 mM ricolinostat, or a
combination for 24 hours. Complementary DNA (cDNA) from control
and treated cells was used for relative quantification by real-time
polymerase chain reaction (RT-PCR) analyses. First-strand cDNA
synthesis was performed with 1 mg RNA in a 20-mL reaction
mixture using the high-capacity cDNA Reverse Transcription Kit
(Applied Biosystems).HDAC6, c-MYC, andCDKN1A transcripts
were amplified using commercially available TaqMan gene ex-
pression assays (Applied Biosystems). GAPDH was used as a
housekeeping gene.
Human RPMI-8226 MM cells (1 3 107) were implanted into
8-week-old female SCID mice. Treatment was initiated when
tumors reached a size of approximately 150 mm3. Mice were
treated with 50 mg/kg JQ1, 50 mg/kg ricolinostat, or both agents
intraperitoneally once per day for 5 days per week for 3 weeks. Tumor
volume and animal weight were measured twice per week. Animal
studies were conducted in an unblinded fashion to ensure that mice
in each group received the appropriate treatments.
Immunohistochemistry
Paraffin-embedded tumor sections were deparaffinized in xylene
and a graded series of alcohol solutions and rehydrated in phosphate-
buffered saline (PBS). Heat-induced epitope retrieval on paraffin-
embedded sections was performed by microwaving slides in a
citrate buffer for 5 minutes. Endogenous peroxides were blocked
with a 3% hydrogen peroxide solution for 10 minutes. Slides were
then incubated in a protein block solution (5% horse serum and
1% goat serum in PBS) for 20 minutes. Anti-c-MYC, BCL-2,
PCNA, cleaved caspase-3, and HDAC6 antibodies were diluted in
the protein block solution and stored at 4°C overnight. After
washing with PBS, slides were incubated in goat anti-rabbit or
goat anti-mouse HRP-conjugated secondary antibody for 1 hour
at ambient temperature. Positive reactions were visualized by using
3,39-diaminobenzidine (Dako, Carpinteria, CA) for 10minutes. The slides
were rinsed with water followed by a brief counterstain with Gill’s
hematoxylin (Sigma, St. Louis, MO). Images were captured by using an
Olympus fluorescent microscope (Center Valley, PA) with a DP71
camera and an 320 objective. Image-Pro Plus software Version 6.2.1
(MediaCybernetics, Bethesda, MD) was used for image acquisition.
ImageJ software was used for quantification of c-MYC and BCL-2 levels
by densitometric analysis of 5 random fields containing viable tumor
cells. Quantification of PCNA and cleaved caspase-3 was conducted
by counting the number of positive cells in 5 random fields.
Statistical analyses
Power calculations were performed to determine the appropriate
sample size for all experiments included in this study. Ten mice per
group were used in all animal studies on the basis of statistical
considerations. Statistical significance between samples was de-
termined by using the Tukey-Kramer comparison test or the Student t
test as appropriate. Differences were considered significant in all
experiments at P , .05.
Results
BET inhibition induces expression of the prosurvival
factor HDAC6 in MM cells
In support of a key role for BET activity in MM pathogenesis, treatment
of a panel of 10 MM cell lines with the BET antagonist JQ1 led to
diminished MM cell viability (Figure 1A). Further analysis by
quantitative RT-PCR and immunoblotting revealed that JQ1 treat-
ment significantly reduced the levels of c-MYC and increased p21 in
a dose- and time-dependent manner (Figure 1B-C). Consistent with
these alterations, JQ1 treatment also promoted the induction of
apoptosis (Figure 1D). JQ1 and other BET antagonists are not
targeted MYC inhibitors. Although they have been shown to
transcriptionally repress key oncogenic proteins such as c-MYC,
BCL-2, cyclin D1, and CDK6, they may simultaneously induce
other prosurvival genes that limit efficacy. To better understand
genes related to protein ubiquitination and degradation that may
be modulated after JQ1 treatment, we performed microarray
analysis on LP-1 and OPM-2 MM cells. We noted that HDAC6
was significantly upregulated in both MM cell lines, suggesting
that it may be a pharmacodynamic regulator of sensitivity to JQ1
(Figure 2A). HDAC6 has been shown to promote tumor cell
growth, activate c-MYC, participate in ubiquitin-conjugated pro-
tein aggresome formation, and contribute to drug resistance.17-19
Therefore, it has emerged as a promising target for cancer therapy.20
JQ1 treatment induced a significant increase in HDAC6 expression
at both the transcript (Figure 2B) and protein (Figure 2C) level in
MM cell lines. In addition, JQ1 significantly upregulated HDAC6
expression in CD1381 cells collected from MM patients (Figure 3D).
Notably, this effect was also dose and time dependent (Figure 3A-B).
To further evaluate the role of HDAC6 in BET inhibitor sensitivity, we
silenced its expression using lentiviral shRNA, which resulted in a
modest decrease in c-MYC and BCL-2 (Figure 3C). We hypothe-
sized that BET inhibitor–mediated HDAC6 induction would signifi-
cantly reduce its anti-MM efficacy. In support of the antagonistic
nature of this pharmacodynamic effect, shRNA-mediated silenc-
ing of HDAC6 significantly enhanced the anticancer activity of
JQ1 in both LP-1 and RPMI-8226 MM cells (Figure 3D). Conversely,
overexpression of HDAC6 (supplemental Figure 1A) resulted
in reduced efficacy of JQ1 (supplemental Figure 1B). Taken
together, these results demonstrate that differing levels of HDAC6
expression are sufficient to modulate the cellular sensitivity to BET
inhibitors.
Ricolinostat is a selective HDAC6 inhibitor with
significant efficacy against MM cells
To further investigate the role of HDAC6 in BET inhibitor resistance,
we used the selective HDAC6 inhibitor ricolinostat (ACY-1215),
which is currently under clinical investigation for the treatment of MM
and other malignancies.21 Single-agent treatment with ricolinostat
diminished cell viability in a panel of MM cell lines (Figure 4A).
Importantly, ricolinostat selectively increased acetylated a-tubulin,
a marker of HDAC6 inhibition, without altering acetylated histone
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H4 (a marker of global HDAC inhibition) at biologically relevant
concentrations (,10 mM) (Figure 4B). Therefore, we used 3 mM
or less ricolinostat in all additional assays to achieve selective
inhibition of HDAC6 activity. Importantly, shRNA-mediated knock-
down of BRD4 decreased the expression of c-MYC and BCL-2
while also upregulating p21 and HDAC6 (Figure 4C). Silencing
BRD4 also significantly enhanced the antimyeloma activity of
ricolinostat (Figure 4D). Collectively, these data establish proof of
concept that simultaneous targeting of BRD4 and HDAC6 may be
an effective antimyeloma strategy.
Ricolinostat enhances the antimyeloma activity of JQ1
To investigate the potential benefit of this therapeutic approach,
we evaluated the anticancer effects of JQ1 in combination with
ricolinostat in MM models and primary patient specimens. Inhibition of
HDAC6 activity with ricolinostat enhanced JQ1-mediated suppression
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Figure 1. JQ1 reduces the cell viability of MM cells, modulates c-MYC and p21 expression, and induces apoptosis. (A) JQ1 decreases MM cell viability. A panel of
MM cell lines was treated with the indicated concentrations of JQ1 for 72 hours. Cell viability was measured by MTT assay. (B) Quantitative RT-PCR (qRT-PCR) analysis of
c-MYC and CDKN1A levels. MM cells were treated with 500 nM JQ1 for 24 hours, and gene expression was measured by qRT-PCR. (C) JQ1 treatment decreases c-MYC
protein expression and induces p21. RPMI-8226, LP-1, and OPM-2 MM cells were treated with the indicated concentrations of JQ1 for 24 hours (left) or 500 nM JQ1 (right)
for the indicated times. Protein expression was determined by immunoblotting. (D) JQ1 stimulates apoptosis in MM cell lines. LP-1 and OPM-2 MM cells were treated with the
indicated concentrations of JQ1 for 48 hours. Apoptosis was determined by propidium iodide fluorescence-activated cell sorting (PI-FACS) analysis. Data are shown as mean
6 standard deviation (SD); n 5 3. *Indicates a significant difference from controls. P , .05.
23 APRIL 2019 x VOLUME 3, NUMBER 8 HDAC6 BLOCKADE ENHANCES BET INHIBITOR THERAPY 1321
.For personal use only on August 20, 2019. at University of Arizona Health Sciences Library www.bloodadvances.orgFrom 
B
JQ1
Control
OPM2
HDAC6
OPM2
JQ1
LP1 LP1
Attribute
-1.75 0.00 1.75
Control JQ1 cell line LP1 OPM2
TNKS2
AMFR
TRIM38
MARCH6
NPEPPS
UBE2A
TRAF6
TNKS
UBE2H
DZIP3
RNF41
CHFR
DDB2
ASB2
DTL
UBE2C
BRCA1
PSMB10
PSMA6
UBE2G2
BLMH
TRAF2
PSMB8
CDC26
CDC23
ANAPC13
PSMB5
ERCC8
KLHL42
PSMA3
ANAPC1
SKP 2
FBX04
PSMB2
PRPF19
PSME3
ZNF738
ANAPCI0
PSME2
UBE2T
A
2.5
2
1.5
1
0.5
0
CD138+ primary MM cells
Control JQ1
*
DC
JQ1 - +
HDAC6
Tubulin
LP-1
JQ1 - +
HDAC6
Tubulin
OPM-2
(fo
ld 
inc
re
as
e 
fro
m
 c
on
tro
l)
HD
AC
6
0.0
Control JQ1
LP-1
1.0
2.0
3.0
4.0 *
0.0
0.5
Control JQ1
OPM-2
1.0
1.5
2.0
2.5
*
(fo
ld 
inc
re
as
e 
fro
m
 c
on
tro
l)
HD
AC
6
Control JQ1
RPMI-8226
6.0
5.0
4.0
3.0
2.0
1.0
0.0
*
(fo
ld 
inc
re
as
e 
fro
m
 c
on
tro
l)
HD
AC
6
Control JQ1
U266
3.5
3.0
2.5
2.0
1.5
0.5
1.0
0.0
*
(fo
ld 
inc
re
as
e 
fro
m
 c
on
tro
l)
HD
AC
6
HD
AC
6
(fo
ld 
inc
re
as
e 
fro
m
 c
on
tro
l)
Figure 2. JQ1 induces HDAC6 expression in MM cells. (A) JQ1 treatment upregulates HDAC6 expression. LP-1 and OPM-2 MM cells were treated with 500 nM JQ1 for
24 hours. Gene expression changes were determined using Affymetrix expression arrays. Protein ubiquitination-related genes with significant induction/repression are illustrated
in the heat map. (B) qRT-CR analysis of HDAC6 levels. Four MM cell lines were treated with 500 nM JQ1 for 24 hours, and HDAC6 expression was measured by qRT-PCR.
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of c-MYC and BCL-2 expression (Figure 5A). JQ1 treatment
did not alter the effects of ricolinostat on a-tubulin acetylation
(Figure 5A). In addition, combination treatment resulted in significant
increases in apoptosis induction as evidenced by enhanced caspase-
3 cleavage and DNA fragmentation (Figure 5A-B). Formal synergy
analysis of JQ1 and ricolinostat demonstrated strong synergy at
multiple dose levels in both LP-1 and OPM-2 MM cells (supplemental
Table 1). Notably, the enhancement of the antimyeloma activity of JQ1
by ricolinostat was similar to that of the pan-HDAC inhibitor
vorinostat, indicating that HDAC6 inhibition rather than global
HDAC antagonism may be driving this phenomenon (Figure 5C).
The effectiveness of the JQ1 combination with ricolinostat or
vorinostat was also observed in primary CD1381 cells obtained
from patients with MM (Figure 5D). Importantly, this therapeutic
approach reduced MM cell viability in a manner that was not
affected by prior treatment history (supplemental Table 2). This
suggests, in particular, that patients who have developed resistance
to proteasome inhibitor–based regimens may benefit from targeted
HDAC6 and BET inhibition.
Cotargeting of HDAC6 and BET factors synergistically
antagonizes MM disease progression
We next conducted a xenograft study to investigate the therapeutic
potential of ricolinostat in combination with JQ1 in vivo. The human
MM cell line RPMI-8226 was injected into nude mice to establish
Figure 2. (continued) Data are shown as mean 6 SD; n 5 3. (C) JQ1 increases HDAC6 protein expression. LP-1 and OPM-2 MM cells were treated with the 500 nM JQ1
for 24 hours. HDAC6 protein expression was determined by immunoblotting. (D) qRT-PCR analysis of HDAC6 levels in CD1381 cells collected from MM patients. CD1381
MM cells were treated with 500 nM JQ1 for 24 hours, and HDAC6 expression was measured by qRT-PCR. Data are shown as mean 6 SD; n 5 5. *Indicates a significant
difference from controls. P , .05.
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Figure 3. BET inhibition–mediated upregulation of HDAC6 expression limits its efficacy against MM cells. (A) JQ1 treatment increases HDAC6 protein
expression. LP-1 and RPMI-8226 MM cells were treated with the indicated concentrations of JQ1 for 24 hours. Protein expression was determined by immunoblotting.
(B) JQ1 increases HDAC6 expression in a time-dependent manner. LP-1 and RPMI-8226 MM cells were treated with 500 nM JQ1 for the indicated times. Protein
expression was determined by immunoblotting. (C) Silencing HDAC6 decreases c-MYC and BCL-2 expression. LP-1 cells were infected with nontarget (NT) control or
HDAC6 lentiviral shRNA, and positively infected cells were selected with puromycin. Immunoblotting confirmed knockdown of HDAC6 and decreased levels of c-MYC
and BCL-2. (D) Knockdown of HDAC6 augments the antimyeloma activity of JQ1. LP-1 and RPMI-8226 MM cells were infected with NT control or HDAC6 lentiviral
shRNA. Cells transfected with NT control or HDAC6 shRNA were treated with the indicated concentrations of JQ1 for 72 hours, and cell viability was determined
by MTT assay. Data are shown as mean 6 SD; n 5 3. *Indicates a significant difference compared with NT transfected cells treated with the same concentration.
P , .05.
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xenograft tumors. Mice were randomly assigned into groups with
similar disease burden and then treated with vehicle, 50 mg/kg JQ1,
50 mg/kg ricolinostat, or the combination of both agents once per
day for 5 days for 3 weeks. Disease burden and animal weight were
measured twice per week. Although both JQ1 and ricolinostat each
individually displayed significant antimyeloma activity, combination
treatment resulted in an additional significant reduction in disease
burden compared with either single-agent treatment (Figure 6A).
Importantly, combination therapy was very well tolerated and did not
significantly affect animal weight (less than 5% mean transient
reduction in body weight) (Figure 6B). Consistent with our in
vitro findings, immunohistochemistry analyses revealed that
treatment with JQ1 significantly upregulated HDAC6 expression
in the RPMI-8226 MM xenograft tumors (supplemental Figure 2A-B).
Further immunohistochemical studies demonstrated that the
combination of JQ1 and ricolinostat also led to significantly
reduced MM cell proliferation (PCNA), increased apoptosis
(active caspase-3), and diminished expression of c-MYC and
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Figure 4. Ricolinostat displays antimyeloma activity and its efficacy is enhanced by knockdown of BRD4. (A) Ricolinostat decreases MM cell viability. A panel of MM
cell lines was treated with the indicated concentrations of ricolinostat for 72 hours. Cell viability was measured by MTT assay. (B) Ricolinostat promotes the accumulation of
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selected with puromycin. Immunoblotting confirmed knockdown of BRD4 and levels of c-MYC, BCL-2, p21, and HDAC6. (D) Silencing of BRD4 enhances the antimyeloma activity
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BCL-2 (Figure 6C-D). These data suggest that induction of
HDAC6 may represent a key mechanism of resistance that limits
the efficacy of BET inhibitor therapy (Figure 7). Taken together,
our findings demonstrate that abrogation of HDAC6 activity with
ricolinostat is a novel approach to augment the efficacy of BET
inhibitors in MM that warrants further investigation.
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Figure 6. Ricolinostat enhances the in vivo antimyeloma activity of JQ1. (A) Ricolinostat enhances the antimyeloma activity of JQ1 in vivo. RPMI-8226 tumors were
established in nude mice. Mice were treated with 50 mg/kg JQ1, 50 mg/kg ricolinostat, or the combination of both agents once per day for 5 days per week for 3 weeks.
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Discussion
BET protein family members bind to acetylated lysines on histones
and regulate the expression of many genes, including c-MYC and
BCL-2.8,22 Given the importance of these and other BET targets in
malignant pathogenesis, several targeted BET inhibitors have been
developed, many of which are currently being investigated in the
clinic.12,14,16,23,24 Initial clinical studies have indicated that BET
inhibitors have modest clinical activity in certain hematologic
cancers as monotherapies.13,25 This is certainly promising, but it
also highlights the need to develop novel strategies to improve their
activity on the basis of an understanding of specific mechanisms
that limit their efficacy. We conducted transcriptome analysis
of JQ1-treated MM cells to identify actionable targets that may
augment the efficacy of BET inhibitors. Here we show that HDAC6
is significantly upregulated after JQ1 treatment, and its blockade
enhances BET inhibitor therapy in MM. Several reports have
determined that pan-HDAC inhibitors synergize with JQ1 to
suppress tumor growth and this effect has been attributed to
several mechanisms, including the repression of c-MYC and in-
flammatory cascades that control levels of interleukin-6.22,26,27 The
general concept of the therapeutic benefit of dual HDAC6 and
BET inhibition has recently been observed in lung cancer
models. However, the mechanistic basis for this benefit seems
to be different in lung cancer than in MM. In lung cancer, the
combination improved T-cell function and natural killer cell
activation, whereas our study pointed to c-MYC and BCL-2
suppression driving the anticancer efficacy in MM.28,29 In
addition, unlike our work in MM models, the studies in lung
cancer models failed to demonstrate significant anticancer
effects of this combination in vitro.29 Perhaps this was the result
of the heightened intrinsic sensitivity of MM cells to antagonism
of both of these targets. This seems to be supported by clinical
studies in which HDAC6 and BET inhibition has demonstrated better
efficacy in patients with hematologic malignancies.13,25,30,31 Regard-
less of the specific basis for this phenomenon, our data combined
with those from recent lung cancer studies support that this
combination strategy has promising anticancer activity that is
worthy of further investigation.
Ricolinostat is a first-in-class selective HDAC6 inhibitor that is 10-
to 15-fold more selective for HDAC6 than HDAC1-3.21 HDAC6
has been shown to play a key role in promoting drug resistance,
and inhibition of its activity enhances the activity of other agents,
including bortezomib.19,32,33 These observations have resulted
in the clinical investigation of ricolinostat in combination with
standard chemotherapy for the treatment of MM and other
malignancies.30,31 Our study demonstrates that selective HDAC6
antagonism augments the activity of JQ1 in a manner similar to
that of vorinostat against MM cell lines and primary patient
specimens. The use of HDAC6 selective inhibitors over pan-
HDAC inhibitors may provide a significant therapeutic advantage
that maintains maximum efficacy while limiting the adverse effects
associated with global HDAC inhibition. Indeed, our study showed
that JQ1 and ricolinostat combination therapy was effective
and well tolerated in our MM mouse model. In addition, the
combination also exhibited significant and equipotent antimye-
loma activity in a panel of CD1381 cells obtained from MM
patients with varying cytogenetic characteristics and treatment
histories.
Previous studies have demonstrated that ectopic expression of c-
MYC reduces the anticancer activity of JQ1, affirming the
importance of c-MYC suppression as a key mechanism of action
of BET inhibitors.2,8 Furthermore, several studies investigating drug
resistance to BET inhibitors identified the reactivation of BRD4-
dependent genes, in particular restoration of c-MYC expression, as
a major underlying mechanism.34-37 Our study identifies a new
pathway that reduces the efficacy of BET inhibition: pharmacody-
namic upregulation of HDAC6. Although we previously demonstrated
that HDAC6 is a c-MYC transcriptional target, JQ1-mediated
upregulation of HDAC6 is likely regulated by another transcription
factor because c-MYC is significantly downregulated by BET
inhibition.10 Potential candidates that may regulate HDAC6
expression after treatment with JQ1 include FOXO3a and ATF3,
which have recently been shown to associate with HDAC6.38,39
Additional studies that identify the key regulators of HDAC6
Figure 6. (continued) Tumor volume was measured twice per week. Data are shown as mean 6 standard error of the mean; n 5 10. (B) JQ1 and ricolinostat are well
tolerated in mice. RPMI-8226 tumors were established in nude mice, and mice were treated as described above. Mouse body weight was measured twice per week. Data
are shown as mean 6 SD; n 5 10. No significant weight loss was observed in any of the treatment groups compared with vehicle control. (C) Tumors were collected at the end of
study, and levels of c-MYC, BCL-2, PCNA, and cleaved caspase-3 were measured by immunohistochemistry. Scale bars, 50 mm. (D) Immunohistochemical analysis shows that
administration of JQ1 and ricolinostat effectively reduces c-MYC and BCL-2 expression, decreases PCNA1 cells, and induces significant caspase-31 cells. Quantification
of immunohistochemical analysis of c-MYC and BCL-2 was determined by densitometry (relative expression). PCNA and active caspase-3–positive cells were determined by manual
counting. Data are shown as mean 6 SD; n 5 5 random fields. *Indicates a significant difference compared with vehicle; **indicates either single-agent treatment. P , .05.
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Figure 7. HDAC6 inhibition improves the efficacy BET antagonists. Inhibition
of BET activity with JQ1 or BRD4 shRNA decreases c-MYC levels but also induces
HDAC6 expression. Upregulation of HDAC6 has been associated with cancer
progression and drug resistance and has been established as a potential anticancer
target. Antagonizing HDAC6 with shRNA, the HDAC6 selective inhibitor ricolinostat,
or the pan-HDAC inhibitor vorinostat blocks HDAC6 activity and augments the
antimyeloma activity of BET inhibition.
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expression after therapy with a BET inhibitor may provide
important insight into how to limit its upregulation.
In addition to the direct benefit of antagonizing HDAC6-regulated
survival pathways, selectively inhibiting HDAC6 also augments BET
inhibitor–mediated downregulation of c-MYC, which likely contrib-
utes to the synergistic antimyeloma activity of the JQ1-ricolinostat
combination. Collectively, our findings provide the scientific ratio-
nale for clinically testing the combination of ricolinostat and BET
inhibitor targeted therapy for patients with MM. Our study also
demonstrates proof of concept that HDAC6 inhibition is a novel
precision approach to augment BET inhibitor therapy especially
in cell types in which BET inhibitor monotherapy only partially
diminishes c-MYC expression or is rapidly restored after BET
inhibitor therapy.
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